Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials
- 17 July 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 126 (3) , 349-356
Abstract
Background—: Nearly all available treatments for pulmonary arterial hypertension have been approved based on change in 6-minute walk distance (Δ6MWD) as a clinically important end point, but its validity as a surrogate end point has never been shown. We aimed to validate the difference in Δ6MWD against the probability of a clinical event in pulmonary arterial hypertension trials. Methods and Results—: First, to determine whether Δ6MWD between baseline and 12 weeks mediated the relationship between treatment assignment and development of clinical events, we conducted a pooled analysis of patient-level data from the 10 randomized placebo-controlled trials previously submitted to the US Food and Drug Administration (n=2404 patients). Second, to identify a threshold effect for the Δ6MWD that indicated a statistically significant reduction in clinical events, we conducted a meta-regression among 21 drug/dose-level combinations. Δ6MWD accounted for 22.1% (95% confidence interval, 12.1%– 31.1%) of the treatment effect ( P <0.001). The meta-analysis showed an average difference in Δ6MWD of 22.4 m (95% confidence interval, 17.4–27.5 m), favoring active treatment over placebo. Active treatment decreased the probability of a clinical event (summary odds ratio, 0.44; 95% confidence interval, 0.33–0.57). The meta-regression revealed a significant threshold effect of 41.8 m. Conclusions—: Our results suggest that Δ6MWD does not explain a large proportion of the treatment effect, has only modest validity as a surrogate end point for clinical events, and may not be a sufficient surrogate end point. Further research is necessary to determine whether the threshold value of 41.8 m is valid for long-term outcomes or whether it differs among trials using background therapy or lacking placebo controls entirely.Keywords
This publication has 43 references indexed in Scilit:
- Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management EraCirculation, 2010
- Surrogate and Combined End Points in Pulmonary Arterial HypertensionProceedings of the American Thoracic Society, 2008
- A meta-analysis of trials of pulmonary hypertension: A clinical condition looking for drugs and research methodologyAmerican Heart Journal, 2007
- Epidemiology of Pulmonary Arterial HypertensionClinics in Chest Medicine, 2007
- Surrogate End Points in Pulmonary Arterial Hypertension: Assessing the Response to TherapyClinics in Chest Medicine, 2007
- Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertensionEuropean Heart Journal, 2006
- A perfect correlate does not a surrogate makeBMC Medical Research Methodology, 2003
- Long-term intravenous epoprostenol infusion in primary pulmonary hypertensionJACC, 2002
- Clinical Correlates and Prognostic Significance of Six-minute Walk Test in Patients with Primary Pulmonary Hypertension: Comparison with Cardiopulmonary Exercise TestingAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Surrogate endpoints in clinical trials: Definition and operational criteriaStatistics in Medicine, 1989